Leerink said the report that CVS Health (CVS) has likely reached a proposed settlement with the FTC isn’t a major surprise. However, the firm added that completing any settlement is an incremental positive as it removes an “air of uncertainty” from a pharmacy benefit management business that has had numerous recent overhangs. Leerink reiterated an Outperform rating and $98 price target on CVS Health shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health reaches settlement with FTC for insulin pricing, Reuters reports
- CVS Health close to settlement with FTC, says JPMorgan
- Sonoma announces U.S. retail launch of advanced burn relief hydrogel
- CVS Health put volume heavy and directionally bearish
- CVS Health Adds Veteran Finance Leader to Board